VOR Vor Biopharma

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit

Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET

Location: Virtual

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contact:

Media & Investors

Sarah Spencer





EN
27/11/2023

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for P...

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment ...

4h / 16m 1 EN
Wedbush Research
  • Wedbush Research
PHM PULTEGROUP INC.
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
SE SEA ADS
STOK STOKE THERAPEUTICS
PASG PASSAGE BIO
ORIC ORIC PHARMACEUTICALS
GBIO GENERATION BIO
VOR VOR BIOPHARMA
PHVS PHARVARIS NV
ATXS ASTRIA THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
RNAC CARTESIAN THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
9h / 39m 9h / 39m 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
13h / 16m 13h / 16m 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Com...

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. “We’re thrilled to welcome Dallan to Vor Bio at this important inflection point,” said Jean-Paul Kress, M....

August 4, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Mic...

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. Alexander (Bo) Cumbo currently serves as Presiden...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch